BioCentury | Mar 13, 2021
Product Development

Long COVID therapies are starting to populate a sparse pipeline

As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

Even with a COVID-19-related lull in the first half of 2020, investors’ appetite for new biotech listings on NASDAQ far surpassed demand in recent years, leading to a record-setting year for IPOs. According...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Nov 11, 2020
Management Tracks

Novavax brings in Tesaro’s Covino as it readies to market two vaccines; plus moves at Werewolf, Editas, Magenta, Pharming, Marinus and more

Novavax Inc. (NASDAQ:NVAX) hired Gregory Covino as EVP and CFO as the company prepares to commercialize COVID-19 vaccine candidate NVXCoV2373 and flu vaccine NanoFlu. Covino succeeds EVP John Trizzino, who will become chief commercial officer while...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

The Ministry of Health of the Russian Federation has approved a COVID-19 vaccine under emergency rules based on immunogenicity rather than protection data.  While COVID-19 vaccine developers have been gathering safety and immune response data...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
Items per page:
1 - 10 of 827
BioCentury | Mar 13, 2021
Product Development

Long COVID therapies are starting to populate a sparse pipeline

As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

Even with a COVID-19-related lull in the first half of 2020, investors’ appetite for new biotech listings on NASDAQ far surpassed demand in recent years, leading to a record-setting year for IPOs. According...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Nov 11, 2020
Management Tracks

Novavax brings in Tesaro’s Covino as it readies to market two vaccines; plus moves at Werewolf, Editas, Magenta, Pharming, Marinus and more

Novavax Inc. (NASDAQ:NVAX) hired Gregory Covino as EVP and CFO as the company prepares to commercialize COVID-19 vaccine candidate NVXCoV2373 and flu vaccine NanoFlu. Covino succeeds EVP John Trizzino, who will become chief commercial officer while...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

The Ministry of Health of the Russian Federation has approved a COVID-19 vaccine under emergency rules based on immunogenicity rather than protection data.  While COVID-19 vaccine developers have been gathering safety and immune response data...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

AstraZeneca and Oxford will likely move forward with a two-dose schedule for their adenoviral vaccine following an anticipated Phase I/II readout, a decision that could shift timelines, availability and tolerability of one of the COVID-19...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
Items per page:
1 - 10 of 827